UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2024
(Exact name of registrant as specified in charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | |||||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||
(781 ) 890-9989
(Registrant’s telephone number, including area code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Stockholders of NeuroMetrix, Inc. (the “Company”) was held in a virtual format on April 30, 2024 (the “Annual Meeting”). Of the Company’s 1,986,540 shares of common stock issued and outstanding and eligible to vote as of the record date of March 4, 2024, a quorum of 1,198,853 shares, or 60.3% of the eligible shares, was present or represented by proxy. Each of the matters set forth below is described in detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on March 27, 2024. The following actions were taken at the Annual Meeting:
a)Election of David Van Avermaete and Bradley Fluegel as Class II Directors of the Company, to serve until the Company’s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
| Voted For | Withheld Authority | |||||||||||||||||||||||||
| David Van Avermaete | 122,336 | 422,884 | ||||||||||||||||||||||||
| Bradley Fluegel | 132,934 | 412,286 | ||||||||||||||||||||||||
After the Annual Meeting, David E. Goodman, M.D., and Nancy E. Katz continued to serve as the Company’s Class III Directors for a term that expires in 2025 and Shai N. Gozani, M.D., Ph.D. continued to serve as the Company’s Class I Director for a term that expires in 2026.
b)Ratification of the selection of Baker Tilly US, LLP to serve as the Company’s independent auditors for the fiscal year ending December 31, 2024. The voting results were 1,117,755 votes for, 76,752 votes against, and 4,346 votes abstaining, with no broker non-votes.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEUROMETRIX, INC.
Date: May 1, 2024 By: /s/ Thomas T. Higgins
Thomas T. Higgins
Senior Vice President, Chief Financial Officer and Treasurer